Innovation Seed Grant Fuels Angelman Research

About this program

The Foundation for Angelman Syndrome Therapeutics (FAST) offers the Innovation Seed Grant to advance groundbreaking research in Angelman Syndrome (AS), focusing on high-risk, high-reward ideas at the proof-of-concept stage. Funding ranges from $10,000 to $50,000, supporting early-stage feasibility studies and proof-of-principle data generation. Eligible applicants include individual researchers, multidisciplinary teams, and collaborative partnerships between academic and industry entities, with institutions typically recognized as nonprofit organizations and individuals holding at least a Ph.D. or M.D. equivalent. Proposals must target innovative, untested hypotheses in areas such as treatment strategies, therapeutic targets, and biomarker identification.